US20080305163A1 - Butylphthalide soft gel capsule and its preparation procedure - Google Patents
Butylphthalide soft gel capsule and its preparation procedure Download PDFInfo
- Publication number
- US20080305163A1 US20080305163A1 US12/195,360 US19536008A US2008305163A1 US 20080305163 A1 US20080305163 A1 US 20080305163A1 US 19536008 A US19536008 A US 19536008A US 2008305163 A1 US2008305163 A1 US 2008305163A1
- Authority
- US
- United States
- Prior art keywords
- butylphthalide
- oil
- soft gel
- capsule
- gel capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CCCC*1OC(=O)C2=CC=CC=C12 Chemical compound CCCC*1OC(=O)C2=CC=CC=C12 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention relates to a novel dosage form of butylphthalide soft gel capsules and its preparation.
- Butylphthalide is a major ingredient of celery ( Apium graveolens ) and its seeds. It can be extracted from seed oil of natural celery, or obtained from chemical synthesis.
- Chinese patent 98125618. X disclosed applications of L-butylphthalide (levorotatory butylphthalide) in drugs of anti thrombosis and anti platelet aggregation, which clearly demonstrated that butylphthalide has a function of adjusting NOS—NO-cGMP system and nerve cell arachidonic acid metabolism after brain ischemia.
- Chinese patent 93117148.2 disclosed applications of Apigenin A in preparing of medicine for prevention and treatment of the diseases caused by brain ischemia in mammals and human. Apigenin A is in fact the non-optically active form of butylphthalide.
- Butylphthalide is an oily liquid with strong celery smell.
- the chemical structure of butylphthalide is as following:
- the soft gel capsule is a relatively new form of pharmaceutical delivery system, which is especially suitable for orally delivering active ingredients in oil form.
- the main active ingredient is uniformly distributed in the diluting agents and the drug dosage is measured accurately in each capsule.
- the out surface of the capsule is smooth and round, so that the capsule can be easily swallowed by the patient, therefore the patient compliance of the soft gel capsule is good.
- This invention discloses a novel butylphthalide soft gel capsule form based on our research and development on the physical and chemical characteristic of butylphthalide and utilization of the special advantage of soft gel capsule.
- the purpose of the invention is to provide a butylphthalide soft gel capsule.
- butylphthalide soft gel capsule is comprised of capsule materials and drug-containing oil, in which the drug-containing oil is comprised of butylphthalide and diluent vegetable oil basically.
- the weight ratio between butylphthalide and diluent vegetable oil ranges from 1:0 to 1:10 (w/w).
- certain amount of antioxidant dibutyl carboxyl methyl benzene dibutyl carboxyl toluene can be added to the vegetable oil.
- Butylphthalide in this invention means the optically inactive, mixed L and D forms of butylpthalide, and/or levorotatory optical isomer of butylphthalide, and/or dextrorotatory optical isomer of butylphthalide. Their appearances are all in the oily liquid form.
- the vegetable oil can be selected from a group of oils consisting of sesame oil, corn oil, peanut oil, soybean oil, almond oil, peach kernel oil, cottonseed oil, sunflower seed oil, olive oil, or a mixture of them.
- Capsule materials are basically comprised of gel materials, plasticizer and water.
- the composition weight ratio between gel, plasticizer and water is: 1:0.2 to 0.4:0.8 to 1.3.
- Suitable antiseptic agents can be added to the capsule materials, such as ethyl p-hydroxybenzoate or methyl p-hydroxybenzoate.
- Gel materials can be selected from one of gelatin or acacia gum (Gum Arabic), or a mixture of the two.
- Plasticizer which makes the capsule soft and elastic, can be selected from one of glycerol (glycerin) or sorbitol (sorbierite), or a mixture of the two.
- butylphthalide soft gel capsule can be made by a number of conventional soft gel capsule manufacture methodologies, such as manually molding press method, rotary molding press method or dripping molding method.
- press method such as rotary molding press method.
- This invention chooses the soft gel capsule as a new pharmaceutical delivery form for butylphthalide, which is able to mask its characteristic strong smell. Meanwhile the new preparation, soft gel capsule, overcomes the difficulty of other oral delivery forms of delivering oily active ingredients to patients. The patients can conveniently take the oval shaped soft gel capsule orally and easily swallow them. The patients' compliance of the new delivery form preparation is good.
- butylphthalide soft gel capsule is comprised of capsule materials and drug-containing oil, in which the drug-containing oil is comprised basically of butylphthalide and diluent vegetable oil.
- a relatively better weight ratio of butylphthalide to diluent vegetable oil ranges from 1:1 to 1:8 (w/w).
- the further better selected weight ratio of butylphthalide to diluent vegetable oil ranges from 1:2 to 1:5 (w/w).
- the weight ratio of butylphthalide to diluent vegetable oil is 1:3.5 (w/w).
- Dibutyl carboxyl methylbenzene (dibutyl carboxyl toluene) as an antioxidant with the amount of 0 to 0.2% (weight ratio) can be further added to drug-containing oil.
- a better choice of vegetable oil can be selected from a group of oils consisting of peanut oil, soybean oil, corn oil, and sesame oil.
- the best mode choice of oil is soybean oil.
- Capsule materials are basically comprised of gel, plasticizer and water. Among them, the best mode choice of gel is gelatin, the best mode choice of plasticizer is glycerol.
- Gelatin 100 grams, glycerol 30 grams, water 130 grams and 200 mg ethyl p-hydroxybenzoate.
- Capsule 1 Capsule 2
- Capsule 3 Capsule 4
- Capsule 5 Capsule 6
- Capsule 7 Capsule 8
- Capsule 9 Capsule 10 Content 99.12 98.08 100.02 99.47 99.32 101.38 98.65 98.76 99.25 98.47 (%) Range of 98.08-101.38 Content (%) Standard 0.93 Deviation (%)
- the test results were as follows:
- Capsule 1 Capsule 2
- Capsule 3 Capsule 4
- Capsule 5 Capsule 6
- Capsule 7 Capsule 8
- Capsule 9 Capsule 10 Content 98.33 96.08 99.42 101.73 94.37 100.31 92.65 98.79 102.01 95.78 (%) Range of 92.65-102.01 Content (%) Standard 3.14 Deviation (%)
- Capsule 1 Capsule 2
- Capsule 3 Capsule 4
- Capsule 5 Capsule 6
- Capsule 7 Capsule 8
- Capsule 9 Capsule 10 Content 100.03 99.08 99.42 101.73 98.57 100.31 99.55 98.99 100.11 99.98 (%) Range of 98.57-101.73 Content (%) Standard 0.88 Deviation (%)
- Disintegrating time limit assay was performed according to Chinese Pharmacopoeia, Edition 2000, Part Two, Appendix VA's Disintegrating Time Limit Assay.
- Took butylphthalide control sample about 50 mg, weighed it accurately, put it into a 50 ml graduated flask, added methanol solution to dissolve it and diluted it up to the graduated mark, mixed the solution thoroughly. Accurately measured 5 ml solution from the flask and transferred it to another 50 ml graduated flask, diluted it with methanol up to the graduated mark. This was control solution.
Abstract
The present invention discloses a novel dosage form of butylphthalide soft capsule and its preparation procedure. Butylphthalide soft capsule is composed of a coating material and a drug-containing oil. The drug-containing oil is basically composed of butylphthalide and diluent—vegetable oil, wherein the weight ratio of butylphthalide to oil ranges from 1:0˜10. The coating material is composed of gelatin, plasticizer and water, wherein the weight ratio of gelatin to plasticizer to water is in the range of 1:0.2˜0.4:0.8˜0.3. The butylphthalide soft capsule described in this invention can mask the strong and specific flavor of butylphthalide, and overcome the difficulties associated with formulating oily active agents into other oral preparations. The disintegration time of the soft capsule complies with the requirement of Pharmacopoeia of P.R. China.
Description
- This invention relates to a novel dosage form of butylphthalide soft gel capsules and its preparation.
- Butylphthalide is a major ingredient of celery (Apium graveolens) and its seeds. It can be extracted from seed oil of natural celery, or obtained from chemical synthesis. Chinese patent 98125618. X disclosed applications of L-butylphthalide (levorotatory butylphthalide) in drugs of anti thrombosis and anti platelet aggregation, which clearly demonstrated that butylphthalide has a function of adjusting NOS—NO-cGMP system and nerve cell arachidonic acid metabolism after brain ischemia. Chinese patent 93117148.2 disclosed applications of Apigenin A in preparing of medicine for prevention and treatment of the diseases caused by brain ischemia in mammals and human. Apigenin A is in fact the non-optically active form of butylphthalide. Butylphthalide is an oily liquid with strong celery smell. The chemical structure of butylphthalide is as following:
- The soft gel capsule is a relatively new form of pharmaceutical delivery system, which is especially suitable for orally delivering active ingredients in oil form. The main active ingredient is uniformly distributed in the diluting agents and the drug dosage is measured accurately in each capsule. The out surface of the capsule is smooth and round, so that the capsule can be easily swallowed by the patient, therefore the patient compliance of the soft gel capsule is good.
- This invention discloses a novel butylphthalide soft gel capsule form based on our research and development on the physical and chemical characteristic of butylphthalide and utilization of the special advantage of soft gel capsule.
- The purpose of the invention is to provide a butylphthalide soft gel capsule.
- This invention, butylphthalide soft gel capsule, is comprised of capsule materials and drug-containing oil, in which the drug-containing oil is comprised of butylphthalide and diluent vegetable oil basically. The weight ratio between butylphthalide and diluent vegetable oil ranges from 1:0 to 1:10 (w/w). Besides the main ingredients of the drug-containing oil, certain amount of antioxidant dibutyl carboxyl methyl benzene (dibutyl carboxyl toluene) can be added to the vegetable oil.
- Butylphthalide in this invention means the optically inactive, mixed L and D forms of butylpthalide, and/or levorotatory optical isomer of butylphthalide, and/or dextrorotatory optical isomer of butylphthalide. Their appearances are all in the oily liquid form.
- The vegetable oil can be selected from a group of oils consisting of sesame oil, corn oil, peanut oil, soybean oil, almond oil, peach kernel oil, cottonseed oil, sunflower seed oil, olive oil, or a mixture of them.
- Capsule materials are basically comprised of gel materials, plasticizer and water. The composition weight ratio between gel, plasticizer and water is: 1:0.2 to 0.4:0.8 to 1.3. Suitable antiseptic agents can be added to the capsule materials, such as ethyl p-hydroxybenzoate or methyl p-hydroxybenzoate.
- Gel materials can be selected from one of gelatin or acacia gum (Gum Arabic), or a mixture of the two.
- Plasticizer, which makes the capsule soft and elastic, can be selected from one of glycerol (glycerin) or sorbitol (sorbierite), or a mixture of the two.
- In this invention butylphthalide soft gel capsule can be made by a number of conventional soft gel capsule manufacture methodologies, such as manually molding press method, rotary molding press method or dripping molding method. Usually we select press method such as rotary molding press method. We use automatic rotary capsule molding presser, control its working temperature at 40 to 50 degree C., and ensure each molded soft gel capsule containing sufficient butylphthalide for medicinal use.
- This invention chooses the soft gel capsule as a new pharmaceutical delivery form for butylphthalide, which is able to mask its characteristic strong smell. Meanwhile the new preparation, soft gel capsule, overcomes the difficulty of other oral delivery forms of delivering oily active ingredients to patients. The patients can conveniently take the oval shaped soft gel capsule orally and easily swallow them. The patients' compliance of the new delivery form preparation is good.
- In this invention, butylphthalide soft gel capsule is comprised of capsule materials and drug-containing oil, in which the drug-containing oil is comprised basically of butylphthalide and diluent vegetable oil. A relatively better weight ratio of butylphthalide to diluent vegetable oil ranges from 1:1 to 1:8 (w/w). The further better selected weight ratio of butylphthalide to diluent vegetable oil ranges from 1:2 to 1:5 (w/w). In the best mode, the weight ratio of butylphthalide to diluent vegetable oil is 1:3.5 (w/w). Dibutyl carboxyl methylbenzene (dibutyl carboxyl toluene) as an antioxidant with the amount of 0 to 0.2% (weight ratio) can be further added to drug-containing oil.
- A better choice of vegetable oil can be selected from a group of oils consisting of peanut oil, soybean oil, corn oil, and sesame oil. The best mode choice of oil is soybean oil.
- Capsule materials are basically comprised of gel, plasticizer and water. Among them, the best mode choice of gel is gelatin, the best mode choice of plasticizer is glycerol.
- The following implemented experiments are given to further describe the technical scheme of this invention better. The foregoing description is intended to illustrate and not limit the scope of the invention.
- Preparation of Gelatin Liquid:
- Gelatin 100 grams, glycerol 30 grams, water 130 grams and 200 mg ethyl p-hydroxybenzoate.
- Took gelatin and add certain amount of water, let gelatin absorb water and expend. Meanwhile, put glycerol, ethyl p-hydroxybenzoate, and the rest of the water into a colloidal sol pot, heated them to the temperature of 70 to 80 degree C., mixed them well, then added the water absorbed and expended gelatin into the pot and stirred them thoroughly till they were melted. Kept the temperature of the pot stable for 1 to 2 hours, kept the gel liquid in the pot stable and let it settle down so that the air bubbles in the gel liquid floated to the surface of it. Scraped the bubbles off the gel liquid surface. Used a piece of clean white cloth filtering the gel liquid. Kept the gel liquid temperature stable and waited for its further use. The viscosity of the gelatin liquid is usually 2.8 to 3.2 degree.
- Preparation of Drug-Containing Oil:
- Weighed butylphthalide 100 grams, stirred it thoroughly and mixed it well with clear soybean oil 350 grams. The drug-containing oil was ready for use.
- Press Preparation of Soft Gel Capsules:
- Took prepared gelatin glycerol liquid and butylphthalide drug-containing oil and put each of them into automatic rotary molding capsule presser, controlled its working temperature at 40 to 50 degree C., pressed and produced butylphthalide soft gel capsules, each of them contains 450 mg of drug-containing oil.
- The soft gel capsules press produced according to Experiment 1 method and contained Experiment 1 ratio of drug-containing oil, were in proper outside measurement sizes. The quality test result revealed that they contained uniformly distributed amount of drug-containing oil in each of the capsule. The detailed results were as follows:
-
Sample Capsule 1 Capsule 2 Capsule 3 Capsule 4 Capsule 5 Capsule 6 Capsule 7 Capsule 8 Capsule 9 Capsule 10 Content 99.12 98.08 100.02 99.47 99.32 101.38 98.65 98.76 99.25 98.47 (%) Range of 98.08-101.38 Content (%) Standard 0.93 Deviation (%) - All the rest preparing steps were the same as the steps in Example 1, except that during the preparation of drug-containing liquid steps we did not add any vegetable oil, therefore the final press produced soft gel capsules contained 100 mg drug-containing liquid in each of the capsule.
- Preparation of Gelatin Liquid:
- gelatin 100 grams, glycerol 40 grams, water 120 grams and 200 mg ethyl p-hydroxybenzoate. The rest preparation steps were the same as in Experiment 1.
- Preparation of Drug-Containing Oil:
- Weighed butylphthalide 225 grams, stirred it thoroughly and mixed it well with clear peanut oil 225 grams. The drug-containing oil was ready for use.
- Press Preparation of Soft Gel Capsules:
- All the rest preparing steps were the same as the steps in above mentioned other Experiments, except that the final press produced soft gel capsules contained 200 mg drug-containing oil in each of the capsule.
- The soft gel capsules press produced according to Experiment 3 method and contained Experiment 3 ratio of drug-containing oil, were tested. The test results were as follows:
-
Sample Capsule 1 Capsule 2 Capsule 3 Capsule 4 Capsule 5 Capsule 6 Capsule 7 Capsule 8 Capsule 9 Capsule 10 Content 98.33 96.08 99.42 101.73 94.37 100.31 92.65 98.79 102.01 95.78 (%) Range of 92.65-102.01 Content (%) Standard 3.14 Deviation (%) - All the rest preparing steps were the same as the steps in Experiment 1, except during the preparation of drug-containing oil steps we weighed butylphthalide 56.25 grams, stirred it thoroughly and mixed it well with clear peanut oil 393.75 grams, therefore the final press produced soft gel capsules contained 800 mg drug-containing oil in each of the capsule.
- The soft gel capsules pressed according to Experiment 4 method and contained Experiment 4 ratio of drug-containing oil, were tested.
- The test results are as follows:
-
Sample Capsule 1 Capsule 2 Capsule 3 Capsule 4 Capsule 5 Capsule 6 Capsule 7 Capsule 8 Capsule 9 Capsule 10 Content 100.03 99.08 99.42 101.73 98.57 100.31 99.55 98.99 100.11 99.98 (%) Range of 98.57-101.73 Content (%) Standard 0.88 Deviation (%) - Preparation of Gelatin Liquid:
- Gelatin 100 grams, glycerol 20 grams, water 80 grams and 200 mg ethyl p-hydroxybenzoate. The rest preparation steps were the same as in Experiment 1.
- Preparation of Drug-Containing Oil:
- Weighed butylphthalide 45 grams, stirred it thoroughly and mixed it well with clear peanut oil 405 grams. The drug-containing oil is ready for use.
- Press Preparation of Soft Gel Capsules:
- All the rest preparing steps were the same as the steps in above mentioned Experiments, except that the final press produced soft gel capsules contained 1000 mg drug-containing oil in each of the capsule.
- All the rest preparing steps were the same as the steps in Experiment 1, except that during the preparation of drug-containing oil steps we weighed butylphthalide 90 grams, stirred it thoroughly and mixed it well with clear soybean oil 360 grams, therefore the final press produced soft gel capsules contained 500 mg drug-containing oil in each of the capsule.
- All the rest preparing steps were the same as the steps in Experiment 1, except that during the preparation of drug-containing oil steps we weighed butylphthalide 40.91 grams, stirred it thoroughly and mixed it well with clear soybean oil 490.09 grams, therefore the final press produced soft gel capsules contain 1100 mg drug-containing oil in each of the capsule.
- All the rest preparing steps were the same as the steps in Experiment 1, except that during the preparation of drug-containing oil steps we weighed butylphthalide 50 grams, stirred it thoroughly and mixed it well with clear soybean oil 400 grams, therefore the final press produced soft gel capsules contained 900 mg drug-containing oil in each of the capsule.
- All the rest preparing steps were the same as the steps in Experiment 1, except that during the preparation of drug-containing oil steps we weighed butylphthalide 150 grams, stirred it thoroughly and mixed it well with clear soybean oil 300 grams and antioxidant ethyl p-hydroxybenzoate 0.45 grams, therefore the final press produced soft gel capsules contained 300.3 mg drug-containing oil in each of the capsule.
- Assay Method
- Disintegrating Time Limit Assay
- Disintegrating time limit assay was performed according to Chinese Pharmacopoeia, Edition 2000, Part Two, Appendix VA's Disintegrating Time Limit Assay.
- Took samples from Experiment 1, used diluted hydrochloric acid (9→1000) 1,000 ml as solvent, set testing temperature at 37 degree C.+/−1 degree C., set speed of raising and submerging the capsule at 30 to 32 times per minute, added baffle while testing, and observed the total disintegrating time of each soft gel capsule. The result indicated that the disintegrating time was less than 1 hour, which pass the standard of Chinese Pharmacopoeia.
- Relevant Materials
- Relevant materials were tested according to Chinese Pharmacopoeia, Edition 2000, Part Two, Appendix VD's HPLC (High Performance Liquid Chromatography) Assay.
- Assay Method
- Took adequate amount of content from this product, added proper amount chloroform until it was dissolved. Added methanol up to constant volume, diluted and prepared it with methanol until its concentration was 0.5 mg per 1 ml. This was the test solution.
- Weighed butylphthalide adequate amount as assay control accurately, added methanol until it was dissolved, diluted and prepared it with methanol to the concentration of 15 micro gram (μg) butylphthalide per 1 ml. This was the assay control solution.
- Measured assay control solution 20 micro liter (μl) accurately, ejected it into HPLC, tested it according to HPLC menu, adjusted the sensitivity of HPLC until the major composition peak measurement was 10 to 20% of the total measurement.
- Measured test solution 20 micro liter (μl) accurately, tested it the same way as testing the assay control solution on HPLC. Recorded chromatogram up to two folds of the retention time of the chromatographic measurement of the major composition peak. If impurity peaks were existed on the chromatogram, calculated the areas of every impurity peak (except the solvent peak), and the total areas of the impurity peaks should be no larger than the area of the assay control solution peak.
- Content Assay
- Content was tested according to Chinese Pharmacopoeia, Edition 2000, Part Two, Appendix VD's HPLC (High Performance Liquid Chromatography) Assay.
- Testing of Chromatographic Condition and System Serviceability
- Employed octadecyl silane bonded silica gel as filling, methanol-water (65:35) as flow phase, set flow rate at 1.0 ml per minute, assay wave length at 280 nm, theoretical board calculated the number of butylphthalide peaks should be no less than 1500. Butylphthalide versus impurity separation levels should be within the standard.
- Control Solution Preparation
- Took butylphthalide control sample about 50 mg, weighed it accurately, put it into a 50 ml graduated flask, added methanol solution to dissolve it and diluted it up to the graduated mark, mixed the solution thoroughly. Accurately measured 5 ml solution from the flask and transferred it to another 50 ml graduated flask, diluted it with methanol up to the graduated mark. This was control solution.
- Assay Solution Preparation
- Took adequate amount of butylphthalide content from the packages under the stock packaging difference (equivalent to about butylphthalide 50 mg), weighed it accurately, put it into a 50 ml graduated flask, added proper amount chloroform to dissolve it and proper amount of methanol to dilute it up to the graduated mark, stirred and mixed the solution thoroughly. Accurately measured 5 ml solution from the flask and transferred it to another 50 ml graduated flask, diluted it with methanol up to the graduated mark. This was test solution.
- Assay Method
- Measured control solution 20 micro liter (μl) and test solution 20 micro liter (μl) accurately, ejected both of them into HPLC respectively, tested them according to HPLC menu, and recorded their chromatograms respectively. Calculated the peak areas of butylphthalide (C12H14O2) content according to external standard method, recorded the data.
- The experiment data as follows:
-
Observation Relevant Condition Content Substance Disintegration Environment Time Appearance (%) (%) Time Initial 0 Day Yellow transparent soft gel capsule 98.8 0.61 4′50″ Accelerated 1 month Yellow transparent soft gel capsule 98.7 0.66 6′45″ Experiment 2 month Yellow transparent soft gel capsule 99.3 0.63 14′10″ 3 month Yellow transparent soft gel capsule 98.4 0.62 28′30″ 6 month Yellow transparent soft gel capsule 99.0 0.58 49′52″ Room 1 month Yellow transparent soft gel capsule 98.6 0.63 5′15″ Temperature 3 month Yellow transparent soft gel capsule 98.8 0.67 8′35″ Control 6 month Yellow transparent soft gel capsule 99.4 0.66 9′45″ Sample 12 month Yellow transparent soft gel capsule 99.1 0.62 17′50″ 18 month Yellow transparent soft gel capsule 98.5 0.64 27′25″ 24 month Yellow transparent soft gel capsule 98.5 0.65 29′35″ - Most soft gel capsule dosage forms suffer from the problem of product disqualification due to disintegrating time limit when the capsules pass extended shelf storage time. Even though, the test results of accelerated assay and long term assay of the present product indicate that the soft gel capsule shell ages fast and disintegrating time changes more obviously under the heated condition, the disintegrating time is less than 60 minutes. These test results meet the standard of Chinese Pharmacopoeia, Edition 2000. All the indexes of appearance, content, relevant materials of the soft gel capsule have passed the standard levels, and the product's quality is guaranteed up to 2 years.
Claims (11)
1. A butylphthalide soft gel capsule characterized by a composition comprising capsule materials and pharmaceutical components in drug-containing oil form, wherein the pharmaceutical components in drug-containing oil comprising substantially butylphthalide and vegetable oil with the weight ratio in between 1:0 and 1:10.
2. The butylphthalide soft gel capsule according to claim 1 , wherein the characterized weight ratio between butylphthalide and vegetable oil ranges from 1:1 to 1:8.
3. The butylphthalide soft gel capsule according to claim 2 , wherein the characterized weight ratio of said butylphthalide and said vegetable oil ranges from 1:2 to 1:5.
4. The butylphthalide soft gel capsule according to claim 3 , wherein the characterized weight ratio between butylphthalide and vegetable oil is 1:3.5.
5. The butylphthalide soft gel capsule according to claim 1 , 2 , 3 , or 4, wherein the characterized vegetable oil is selected from the group consisting of sesame oil, corn oil, peanut oil, soybean oil, almond oil, peach kernel oil, cottonseed oil, sunflower seed oil, olive oil, or their mixture.
6. The butylphthalide soft gel capsule according to claim 1 , 2 , 3 , or 4, wherein the characterized butylphthalide includes the optically inactive, mixed L and D forms of butylphthalide, levorotatory optical isomer of butylphthalide, dextrorotatory optical isomer of butylphthalide.
7. The butylphthalide soft gel capsule according to claim 1 , wherein the characterized drug-containing oil further includes dibutyl carboxyl methyl benzene (dibutyl carboxyl toluene) as antioxidant with 0 to 0.2% weight ratio in respect to drug-containing oil.
8. The butylphthalide soft gel capsule according to claim 1 , wherein the characterized capsule materials includes the basic components of gel, plasticizer and water with the weight ratio of 1:0.2 to 0.4:0.8 to 1.3.
9. The butylphthalide soft gel capsule according to claim 8 , wherein the characterized gel is selected from the group consisting of gelatin or acacia gum (Gum Arabic), or a mixture of gelatin and acacia gum.
10. The butylphthalide soft gel capsule according to claim 8 , wherein the characterized plasticizer is selected from the group consisting of glycerol (glycerin) or sorbitol (sorbierite), or a mixture of glycerol and sorbitol.
11. The butylphthalide soft gel capsule according to claim 8 , wherein the characterized capsule materials further includes antiseptic agents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/195,360 US20080305163A1 (en) | 2003-12-05 | 2008-08-20 | Butylphthalide soft gel capsule and its preparation procedure |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200310119336.1 | 2003-12-05 | ||
CNB2003101193361A CN1257711C (en) | 2003-12-05 | 2003-12-05 | Butyl benzene phthalein soft capsule and its preparation method |
PCT/CN2004/001411 WO2005053658A1 (en) | 2003-12-05 | 2004-12-03 | Butylphthalide soft gel capsule and its preparatin procedure |
US58137007A | 2007-09-12 | 2007-09-12 | |
US12/195,360 US20080305163A1 (en) | 2003-12-05 | 2008-08-20 | Butylphthalide soft gel capsule and its preparation procedure |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/001411 Continuation WO2005053658A1 (en) | 2003-12-05 | 2004-12-03 | Butylphthalide soft gel capsule and its preparatin procedure |
US58137007A Continuation | 2003-12-05 | 2007-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080305163A1 true US20080305163A1 (en) | 2008-12-11 |
Family
ID=34638049
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/581,370 Abandoned US20080020034A1 (en) | 2003-12-05 | 2004-12-03 | Butylphtualide Soft Gel Capsule and Its Preperation Procedure |
US11/445,832 Abandoned US20070134316A1 (en) | 2003-12-05 | 2006-06-02 | Soft capsule of butylphthalide and a process for preparing the same |
US12/195,360 Abandoned US20080305163A1 (en) | 2003-12-05 | 2008-08-20 | Butylphthalide soft gel capsule and its preparation procedure |
US13/092,610 Active 2024-12-11 US8609137B2 (en) | 2003-12-05 | 2011-04-22 | Soft capsule of butylphthalide and a process for preparing the same |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/581,370 Abandoned US20080020034A1 (en) | 2003-12-05 | 2004-12-03 | Butylphtualide Soft Gel Capsule and Its Preperation Procedure |
US11/445,832 Abandoned US20070134316A1 (en) | 2003-12-05 | 2006-06-02 | Soft capsule of butylphthalide and a process for preparing the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/092,610 Active 2024-12-11 US8609137B2 (en) | 2003-12-05 | 2011-04-22 | Soft capsule of butylphthalide and a process for preparing the same |
Country Status (15)
Country | Link |
---|---|
US (4) | US20080020034A1 (en) |
EP (1) | EP1702612B1 (en) |
JP (1) | JP4634394B2 (en) |
KR (1) | KR100761437B1 (en) |
CN (1) | CN1257711C (en) |
AT (1) | ATE427104T1 (en) |
AU (1) | AU2004294254B2 (en) |
BR (1) | BRPI0417339C8 (en) |
CA (1) | CA2549498C (en) |
DE (1) | DE602004020381D1 (en) |
HK (1) | HK1090302A1 (en) |
MX (1) | MXPA06006401A (en) |
NO (1) | NO338520B1 (en) |
RU (1) | RU2322976C1 (en) |
WO (1) | WO2005053658A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100471494C (en) * | 2005-12-24 | 2009-03-25 | 石药集团中奇制药技术(石家庄)有限公司 | Butylphthalide dripping pill and preparing method |
US8026393B2 (en) * | 2006-01-24 | 2011-09-27 | Sucampo Ag | Soft-gelatin capsule formulation |
CN101342152B (en) * | 2007-07-10 | 2010-10-13 | 石药集团中奇制药技术(石家庄)有限公司 | Butylbenzene phthalein tablet and preparation method thereof |
US8726005B2 (en) | 2009-12-10 | 2014-05-13 | George Mason Intellectual Properties, Inc. | Website matching based on network traffic |
CN102058560B (en) * | 2010-12-30 | 2013-07-24 | 张家界茅岩莓有限公司 | Dihydromyricetin soft capsules and preparation method thereof |
CN102178643B (en) * | 2011-04-29 | 2014-05-14 | 石药集团恩必普药业有限公司 | Microemulsion transdermal gel agent of butylphthalide or derivative thereof, and preparation method thereof |
CN103169685B (en) * | 2011-12-23 | 2018-03-06 | 石药集团中奇制药技术(石家庄)有限公司 | A kind of butylphenyl phthaleine controlled release preparation and preparation method thereof |
CN102716121B (en) * | 2012-06-06 | 2017-10-24 | 石药集团中奇制药技术(石家庄)有限公司 | A kind of butylphthalide medicine active composition and preparation method thereof |
CN102716103B (en) * | 2012-07-02 | 2013-12-18 | 西安力邦制药有限公司 | 2, 2', 6, 6'-tetraisopropyl-4, 4'-2-biphenol soft capsule and method for preparing same |
CN109939102B (en) * | 2013-06-13 | 2022-05-17 | 石药集团中奇制药技术(石家庄)有限公司 | Pharmaceutical composition containing butylphthalide and borneol and application thereof |
CN106606498A (en) * | 2016-07-25 | 2017-05-03 | 山东诚创医药技术开发有限公司 | Butylphthalide soft capsule |
CN106580959B (en) * | 2017-01-10 | 2019-04-23 | 山东省立医院 | A kind of butylphenyl phthaleine Nitrendipine soft capsule for alleviating acute ischemic cerebral apoplexy |
CN109432042B (en) * | 2018-12-24 | 2022-04-22 | 石药集团恩必普药业有限公司 | Soft capsule shell and preparation method thereof |
CN112336700B (en) * | 2019-08-08 | 2023-12-01 | 河北菲尼斯生物技术有限公司 | Stable butylphthalide-containing medicament and preparation method thereof |
CN114073694B (en) * | 2020-08-14 | 2024-03-12 | 北京科莱博医药开发有限责任公司 | Butylphthalide preparation and preparation method thereof |
KR102294072B1 (en) | 2020-11-19 | 2021-08-26 | (주)알피바이오 | Composition for plant-based chewable soft capsule and plant-based chewable soft capsule using the same |
KR102523186B1 (en) | 2020-11-19 | 2023-04-18 | (주)알피바이오 | Composition for animal-based chewable soft capsule and animal-based chewable soft capsule using the same |
CN113975242A (en) * | 2021-10-14 | 2022-01-28 | 山东诚创蓝海医药科技有限公司 | Butylphthalide soft capsule for improving oral bioavailability |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3927195A (en) * | 1974-01-31 | 1975-12-16 | Lilly Industries Ltd | Production of capsules |
NL7510104A (en) * | 1975-08-27 | 1977-03-01 | Akzo Nv | PROCESS FOR THE PREPARATION OF AN ORAL ACTIVE PHARMACEUTICAL PREPARATION. |
US4366145A (en) * | 1981-06-24 | 1982-12-28 | Sandoz, Inc. | Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation |
AU552068B2 (en) * | 1981-09-21 | 1986-05-22 | Asama Chemical Co. Ltd. | Preservation of edible oils |
FR2608456B1 (en) * | 1986-12-18 | 1993-06-18 | Mero Rousselot Satia | MICROCAPSULES BASED ON GELATIN AND POLYSACCHARIDES AND PROCESS FOR OBTAINING THEM |
JPH01199958A (en) * | 1987-07-23 | 1989-08-11 | Tsumura & Co | Novel phthalide derivative and its production |
EP0708651B1 (en) | 1993-06-25 | 1999-10-20 | Main Camp Marketing Pty. Ltd. | Therapeutic agent |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
AUPO990397A0 (en) | 1997-10-22 | 1997-11-13 | R.P. Scherer Holdings Pty Ltd | Clear solutions of herbal extracts |
CN1086942C (en) * | 1998-12-18 | 2002-07-03 | 中国医学科学院药物研究所 | Application of butyl phthalide in preparing medicines curing thrombosis and thrombocyte coagulation |
US6800329B2 (en) * | 1999-02-12 | 2004-10-05 | Lts Lohmann Therapie-Systeme Ag | Method for producing film-type dosage |
US6193999B1 (en) * | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
CN1102397C (en) * | 2000-03-01 | 2003-03-05 | 山东绿叶制药股份有限公司 | Chinese angelica root oil soft capsule and its preparing process |
CN1375288A (en) * | 2002-05-13 | 2002-10-23 | 周桂荣 | Composite medicine for treating cerebrovascular diseases |
US20060166931A1 (en) * | 2002-08-21 | 2006-07-27 | Niu Zhan-Qi | Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof |
-
2003
- 2003-12-05 CN CNB2003101193361A patent/CN1257711C/en not_active Expired - Lifetime
-
2004
- 2004-12-03 DE DE602004020381T patent/DE602004020381D1/en active Active
- 2004-12-03 JP JP2006541784A patent/JP4634394B2/en active Active
- 2004-12-03 AU AU2004294254A patent/AU2004294254B2/en active Active
- 2004-12-03 BR BRPI0417339A patent/BRPI0417339C8/en active IP Right Grant
- 2004-12-03 WO PCT/CN2004/001411 patent/WO2005053658A1/en active Application Filing
- 2004-12-03 RU RU2006122207/15A patent/RU2322976C1/en active
- 2004-12-03 EP EP04802425A patent/EP1702612B1/en active Active
- 2004-12-03 US US10/581,370 patent/US20080020034A1/en not_active Abandoned
- 2004-12-03 MX MXPA06006401A patent/MXPA06006401A/en unknown
- 2004-12-03 AT AT04802425T patent/ATE427104T1/en not_active IP Right Cessation
- 2004-12-03 KR KR1020067011030A patent/KR100761437B1/en active IP Right Grant
- 2004-12-03 CA CA2549498A patent/CA2549498C/en active Active
-
2006
- 2006-06-02 US US11/445,832 patent/US20070134316A1/en not_active Abandoned
- 2006-06-20 NO NO20062895A patent/NO338520B1/en unknown
- 2006-11-02 HK HK06112105.1A patent/HK1090302A1/en unknown
-
2008
- 2008-08-20 US US12/195,360 patent/US20080305163A1/en not_active Abandoned
-
2011
- 2011-04-22 US US13/092,610 patent/US8609137B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0417339B1 (en) | 2017-12-19 |
ATE427104T1 (en) | 2009-04-15 |
CN1623542A (en) | 2005-06-08 |
CA2549498C (en) | 2011-07-12 |
BRPI0417339C1 (en) | 2021-05-25 |
BRPI0417339C8 (en) | 2022-02-01 |
RU2322976C1 (en) | 2008-04-27 |
AU2004294254B2 (en) | 2008-02-07 |
US20070134316A1 (en) | 2007-06-14 |
EP1702612A1 (en) | 2006-09-20 |
US20120052117A1 (en) | 2012-03-01 |
NO338520B1 (en) | 2016-08-29 |
DE602004020381D1 (en) | 2009-05-14 |
WO2005053658A1 (en) | 2005-06-16 |
HK1090302A1 (en) | 2006-12-22 |
AU2004294254A1 (en) | 2005-06-16 |
US8609137B2 (en) | 2013-12-17 |
BRPI0417339A (en) | 2007-02-21 |
MXPA06006401A (en) | 2007-11-13 |
JP4634394B2 (en) | 2011-02-16 |
WO2005053658A8 (en) | 2005-10-13 |
EP1702612B1 (en) | 2009-04-01 |
US20080020034A1 (en) | 2008-01-24 |
KR100761437B1 (en) | 2007-10-04 |
NO20062895L (en) | 2006-09-04 |
CN1257711C (en) | 2006-05-31 |
RU2006122207A (en) | 2008-01-10 |
CA2549498A1 (en) | 2005-06-16 |
KR20060105013A (en) | 2006-10-09 |
EP1702612A4 (en) | 2006-12-20 |
BRPI0417339B8 (en) | 2020-06-02 |
JP2007513097A (en) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080305163A1 (en) | Butylphthalide soft gel capsule and its preparation procedure | |
ES2640572T3 (en) | Enhanced parenteral formulations of lipophilic pharmaceutical agents and methods of preparation and use thereof | |
Nau et al. | A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations | |
RU2462250C2 (en) | New composition of cholest-4-en-3-one oxime | |
BG61637B1 (en) | Selegelin-containing composition for subcutaneous application and method for its preparation | |
EP3007714A1 (en) | Composition for the treatment of neurobehavioral disorders | |
SA00210487B1 (en) | Pharmaceutical formulations for topical and oral use | |
CN109276556B (en) | Calcitriol soft capsule | |
CN108324686A (en) | A kind of ellagic acid is from micro emulsion and preparation method thereof | |
CN105030716B (en) | Caffeinum pharmaceutical combination and preparation method thereof | |
CN106214646B (en) | A kind of silibinin meglumine preparation | |
CN110934847A (en) | Preparation method of eldecalcitol soft capsule | |
Thakar et al. | Formulation and evaluation of natural liposomal gel for breast cancer | |
US20080063704A1 (en) | Stable gabapentin compositions | |
CN102525904B (en) | Stable felbinac gel and preparation method thereof | |
MXPA06006269A (en) | Butylphthalide soft gel capsule and its preparatin procedure | |
CN1322860C (en) | Levo carnitine dropping pill and preparation thereof | |
CN102716158A (en) | In-water type mecamylamine and celery seed oil nanoemulsion antihypertensive medicine | |
JPS61200909A (en) | Long-acting composition for filling in capsule | |
JPH0617305B2 (en) | Chemical solution for filling soft capsules | |
WO2015045037A1 (en) | Capsule preparation | |
CN100469360C (en) | Soft capsule of indapamide | |
CN102727670A (en) | Oil-in-water type terazosin-grape seed oil antihypertensive drug | |
CA3081963A1 (en) | Compositions comprising quillaja extract and methods of preparations and use thereof | |
CA2388431C (en) | Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KNOBBE, MARTENS, OLSON, & BEAR, LLP, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNOR:PARAMOUNT BIOSCIENCES, LLC;REEL/FRAME:023079/0800 Effective date: 20090727 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PARAMOUNT BIOSCIENCES, LLC, NEW YORK Free format text: SECURITY INTEREST TERMINATION;ASSIGNOR:KNOBBE, MARTENS, OLSON & BEAR, LLP;REEL/FRAME:033647/0718 Effective date: 20111116 |